RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @acinnacional: Siguen las buenas noticias sobre las vacunas para la #COVIDー19; hoy se publicó en @TheLancet https://t.co/pngxGdGKOL, lo…
RT @Nat_anest: Lancet опубликовал данные 2-й фазы по вакцине от Astra Zeneca: * Через 14 дней после второй дозы у 99% наблюдались достаточ…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/lA0zhBz8Z1
RT @Nat_anest: Lancet опубликовал данные 2-й фазы по вакцине от Astra Zeneca: * Через 14 дней после второй дозы у 99% наблюдались достаточ…
RT @1000genes: Avanzamos: la vacuna de Oxford es mejor tolerada en adultos mayores que jóvenes pero posee inmunogenicidad similar en todos…
RT @teozka: Resultados de fase 2 de vacuna Oxford/AstraZeneca publicados hoy en Lancet. Al ser fase 2 el estudio de enfoca en inmunogenicid…
RT @mariaramirezNY: Los resultados de la fase 2 del ensayo de la vacuna de Oxford explicados (ya está en la fase 3, que es la final y sobre…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @apsmunro: Amazing to share @TheLancet results of robust immune responses in the elderly to the Oxford COVID-19 vaccine, accompanied by…
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @acinnacional: Siguen las buenas noticias sobre las vacunas para la #COVIDー19; hoy se publicó en @TheLancet https://t.co/pngxGdGKOL, lo…
Siguen las buenas respuestas de las vacunas contra coronavirus. Esta vez para los mayores, los anticuerpos generados son muy buenos hasta en personas mayores de 70 años. https://t.co/M5zx1a7e2G
שתי נקודות התורפה הללו, עשויות לגרום לירידה ביעילות החיסון. תוצאות הניסויים בחיסון עד כה מראות תוצאות טובות, עם עליה יפה בנוגדנים מנטרלים לאורך זמן, פעילות של T-cells, ותופעות לוואי קלות למדי. שווה לחכות ולעקוב! לקריאה נוספת: https://t.co/xnR5QJ8VUT htt
@abledoc T cell response is presented here, but it isn't done very clearly.... https://t.co/M7dantcHvI One almost gets the impression that something is being obscured.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/ACdofWVXNm
RT @BTConservatives: Lead author on the efficacy of the Oxford group vaccine (from the Oxford group) published in the world’s foremost medi…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @BTConservatives: Lead author on the efficacy of the Oxford group vaccine (from the Oxford group) published in the world’s foremost medi…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/oVjk8JC2wi
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
@KFL3011 AstraZeneca Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/luZKIwf0JG
RT @ajpollard1: Encouraging results showing the same immune response in our study of ChAdOx1 nCoV-19 in older adults as in younger adults h…
Safety results for AZ Oxford vaccine. https://t.co/chchvXeg0T
@isabelledaniel Besonders erfreulich ist eine Publikation im Lancet von gestern, dass der erste gut untersuchte Vektorenimpfstoff (Astra Zeneca/Oxford) eine sehr gute Wirksamkeit hat und auch bei Älteren nebenwirkungsarm ist. https://t.co/PzSDZu118G
Single-blind, randomised, controlled, phase 2/3 trial @TheLancet @AstraZeneca adenovirus-vector vaccine showed robust humoral & cellular immune responses in older adults. Very encouraging given decreasing immune function with age. https://t.co/f6v
RT @SharkawyMD: This is the first data reporting an excellent safety profile AND immune response in older subjects for a #Covid19 vaccine.…
#COVID19 @TheLancet COVID’s vaccines 👩🏻⚕️🦠😷🖐🏻💦 another one working 👍👍👍👍
RT @acinnacional: Siguen las buenas noticias sobre las vacunas para la #COVIDー19; hoy se publicó en @TheLancet https://t.co/pngxGdGKOL, lo…
RT @EricTopol: Something very positive, not to be taken for granted: the vaccines are working well in people > 65 years old New data from @…
Siguen las buenas noticias sobre las vacunas para la #COVIDー19; hoy se publicó en @TheLancet https://t.co/pngxGdGKOL, los resultados de los estudios fase 2/3 de la vacuna de Oxford. Esta vacuna logra inmunogenicidad en adultos mayores con buena tolerancia
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it.
RT @HashemGhaili: Updates on Oxford COVID-19 Vaccine. Research Paper: https://t.co/T5kgGwqoEc Learn more: https://t.co/6PdSVk83P2 #Coron…
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
También soy fan de los ingleses uk 🇬🇧. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/ZthSvAkD0a
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @MirkoCiminiello: #coronavirus #COVID__19 #antibodytest #facemasks #vaccines #nanotechnology Follow & RT, please. https://t.co/vbHHNQy…
#coronavirus #COVID__19 #antibodytest #facemasks #vaccines #nanotechnology Follow & RT, please. https://t.co/vbHHNQys05
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @QLexPipiens: Quello che dici non ha alcun senso. Mica sono a priori contro i vaccini. Dico solo, questo è un fatto INCONTROVERTIBILE, c…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
More good news on #COVID19 prevention. Researchers from Oxford have announced that their #SARSCoV2 #vaccine, developed in collaboration with AstraZeneca, produces strong immune responses in older adults. https://t.co/67ig7GloR6
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
@buonanno_paolo @elettrolitico @Ruffino_Lorenzo @lorepregliasco Questo è un punto che condivido. Altri gruppi di ricerca sembra si stiano muovendo diversamente https://t.co/OkATRL8ibJ
👀
RT @DamarisIntriago: Pfizer, Moderna y Sputnik V: Nota de prensa. Oxford/AstraZeneca: Paper en The Lancet. Por eso soy fan de la candid…
RT @DamarisIntriago: Pfizer, Moderna y Sputnik V: Nota de prensa. Oxford/AstraZeneca: Paper en The Lancet. Por eso soy fan de la candid…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @ajpollard1: Encouraging results showing the same immune response in our study of ChAdOx1 nCoV-19 in older adults as in younger adults h…
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seguridad, mejor en pacientes de más edad que en jóvenes, y buena estimulación de respuesta inmunitaria tras dosis de refuerzo. https://t
RT @EricTopol: Something very positive, not to be taken for granted: the vaccines are working well in people > 65 years old New data from @…
RT @GlasgowCRF: Results from the @OxfordVacGroup phase 2 study in older adults - Strong immune response in older adults, & well tolerated. 👇
RT @DonaldJensenMD: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV…
14/ Oxford-AZ vaccine is producing immunity, mild side effects! Results published instead of "science by company press release". It can be stored/transported in normal fridges. And ~100 million doses manufactured by end of December? Christmas come early. h
Pfizer, Moderna y Sputnik V: Nota de prensa. Oxford/AstraZeneca: Paper en The Lancet. Por eso soy fan de la candidata a vacuna de los ingleses 🇬🇧❤️💙 https://t.co/Zilut3qxLk
RT @sherezade_mr: Otra vacuna (UK) en jóvenes y mayores. Ensayo clínico de fase 2. Link al artículo científico en la noticia, de los que ti…
https://t.co/STSOaBxiWW #wockhardt #WOCKPHARMA if you intrested in learning how AZ-Oxford vaccine is doing in clinical trials. Wockhardt UK will manufacture this vaccine for UK and most EU countries once approved. *Vaccine appears to be better tolerated i
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/EYLIftX9Mp
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
More good news on #COVID-19 #vaccine development: the Oxford vaccine shows a strong immune response in adults over 60, who are most at risk from the virus. Results of the phase 2/3 trial were published in @TheLancet: https://t.co/I9HViGAmXY In the news: ht
#covid__19 Résumé des données cliniques des 7 #vaccins à l'étude (phases cliniques 2/3) https://t.co/oOkvBeO9KN https://t.co/bvVAmG1uhh
RT @nigelpraities: Nice to see these results announced in an open-access journal paper, rather than a press release... https://t.co/2aBHJvM…
RT @LupitaJuarezH: Vacuna de #Oxford y #AstraZeneca genera respuesta inmune en todas las edades, de acuerdo con los resultados del ensayo c…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
Light at the end of the tunnel!
RT @mariaramirezNY: Los resultados de la fase 2 del ensayo de la vacuna de Oxford explicados (ya está en la fase 3, que es la final y sobre…
RT @Pediatria: Vacuna de Oxford (Lancet. Ojo, son de la fase II, muestra pequeña... pero al menos no son notas de prensa) => A los 14 días…
RT @teozka: Resultados de fase 2 de vacuna Oxford/AstraZeneca publicados hoy en Lancet. Al ser fase 2 el estudio de enfoca en inmunogenicid…
MUY IMPORTANTE
Excellent news
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @HashemGhaili: Updates on Oxford COVID-19 Vaccine. Research Paper: https://t.co/T5kgGwqoEc Learn more: https://t.co/6PdSVk83P2 #Coron…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
#COVIDー19 : essai clinique phase II/III évaluation de l'immunogénicité d'un nouveau vaccin à vecteur d'adénovirus chimpanzé, ChAdOx1 nCoV-19, chez des adultes d'âges différents Oxford Vaccine Group @OxfordVacGroup https://t.co/M8fNwLmVbl https://t.co/YOgHq
RT @Nat_anest: Lancet опубликовал данные 2-й фазы по вакцине от Astra Zeneca: * Через 14 дней после второй дозы у 99% наблюдались достаточ…
RT @GiacomoGorini: Risultati incoraggianti di immunogenicità negli anziani, che dimostrano di poter sviluppare ottime risposte in seguito a…
Questo l'articolo pubblicato ieri su Lancet relativo la #vaccino #Covid_19 #oxfordvaccine Immunogenicità su popolazione anziani >70a e giovani. https://t.co/1lK95wZn94
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @EricBillyFR: Mode info COVID: Apres Pfizer/BNT, Moderna, c'est au tour de AstraZeneca/Oxford de donner des informations de sa PhII/III.…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @zoeharcombe: Contrast this academic paper on the Oxford vaccine with the company press release on the Pfizer vaccine. Neutralising ant…
@macesari
RT @HashemGhaili: Updates on Oxford COVID-19 Vaccine. Research Paper: https://t.co/T5kgGwqoEc Learn more: https://t.co/6PdSVk83P2 #Coron…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @Sander_Lab: More good news. ChadOx is immunogenic in elderlies. https://t.co/MCiDfP2hS2
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @GlasgowCRF: Results from the @OxfordVacGroup phase 2 study in older adults - Strong immune response in older adults, & well tolerated.…
RT @ajpollard1: Encouraging results showing the same immune response in our study of ChAdOx1 nCoV-19 in older adults as in younger adults h…